Details

Last Funding Type

Series B

Last Funding Money Raised

$25M

Industries

Biotechnology,Pharmaceutical,Therapeutics

Founded date

Jan 1, 2017

Number Of Employee

1 - 10

Operating Status

Active

Cybrexa Therapeutics is developing an entirely new class of small molecule DNA repair inhibitors that directly target the tumor microenvironment. This approach leverages a novel tumor-localizing peptide technology developed by an internationally recognized research laboratory at Yale. Our approach will change the paradigm of drug delivery, and it will greatly enhance the therapeutic index. It has the potential to re-define the definition of “drug-like,” which will unlock a vast array of molecules for clinical development. Our collection of tumor-localizing DNA repair inhibitors can be combined with numerous chemotherapies and also radiotherapy, allowing the safe delivery of higher drug doses, with enhanced efficacy.